Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Current Deferred Revenue: 2019-2024

Historic Current Deferred Revenue for Kymera Therapeutics (KYMR) over the last 6 years, with Dec 2024 value amounting to $13.6 million.

  • Kymera Therapeutics' Current Deferred Revenue rose 85.96% to $37.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.2 million, marking a year-over-year increase of 85.96%. This contributed to the annual value of $13.6 million for FY2024, which is 75.16% down from last year.
  • Kymera Therapeutics' Current Deferred Revenue amounted to $13.6 million in FY2024, which was down 75.16% from $54.7 million recorded in FY2023.
  • Kymera Therapeutics' 5-year Current Deferred Revenue high stood at $170.4 million for FY2020, and its period low was $13.6 million during FY2024.
  • Its 3-year average for Current Deferred Revenue is $43.8 million, with a median of $54.7 million in 2023.
  • In the last 5 years, Kymera Therapeutics' Current Deferred Revenue surged by 221.55% in 2020 and then crashed by 75.16% in 2024.
  • Kymera Therapeutics' Current Deferred Revenue (Yearly) stood at $170.4 million in 2020, then plummeted by 40.70% to $101.0 million in 2021, then slumped by 37.39% to $63.3 million in 2022, then decreased by 13.61% to $54.7 million in 2023, then crashed by 75.16% to $13.6 million in 2024.